Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progres… Read more
Biocartis Group NV (BCART) - Total Liabilities
Latest total liabilities as of June 2023: €166.97 Million EUR
Based on the latest financial reports, Biocartis Group NV (BCART) has total liabilities worth €166.97 Million EUR as of June 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biocartis Group NV - Total Liabilities Trend (2012–2022)
This chart illustrates how Biocartis Group NV's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biocartis Group NV Competitors by Total Liabilities
The table below lists competitors of Biocartis Group NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AS Pro Kapital Grupp
F:17E
|
Germany | €63.73 Million |
|
MCOT Public Company Limited
F:OLU
|
Germany | €3.74 Billion |
|
Bekasi Fajar Industrial Estate
JK:BEST
|
Indonesia | Rp1.29 Trillion |
|
LI Ming Development Construction Co Ltd
TWO:6212
|
Taiwan | NT$7.36 Billion |
|
CPE Technology Berhad
KLSE:5317
|
Malaysia | RM23.34 Million |
|
VerticalScope Holdings Inc
TO:FORA
|
Canada | CA$56.96 Million |
|
Noodles & Company
NASDAQ:NDLS
|
USA | $319.47 Million |
Liability Composition Analysis (2012–2022)
This chart breaks down Biocartis Group NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biocartis Group NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biocartis Group NV (2012–2022)
The table below shows the annual total liabilities of Biocartis Group NV from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | €144.56 Million | -18.04% |
| 2021-12-31 | €176.38 Million | +1.55% |
| 2020-12-31 | €173.69 Million | -5.52% |
| 2019-12-31 | €183.84 Million | +253.32% |
| 2018-12-31 | €52.03 Million | +6.30% |
| 2017-12-31 | €48.95 Million | +10.21% |
| 2016-12-31 | €44.42 Million | +32.74% |
| 2015-12-31 | €33.46 Million | +2.23% |
| 2014-12-31 | €32.73 Million | +16.11% |
| 2013-12-31 | €28.19 Million | -4.08% |
| 2012-12-31 | €29.39 Million | -- |